GEMP - Tiziana Life Sciences Files For Small IPO
Quick Take
Tiziana Life Sciences (TLSA) intends to raise gross proceeds of $11.5 million from a U.S. IPO, according to an F-1 registration statement.
The firm is developing therapeutics and diagnosis for cancers and immune diseases.
TLSA is preparing for Phase 3 trials for its lead candidates to begin in 2019, but investors will likely need to wait until at least 2020 before hearing topline results from those trials.
I'll provide a final opinion when we learn more IPO details from management.
Company & Technology
The Mayfair, UK-based biotechnology company was founded